

# Serge Cremers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5650370/publications.pdf>

Version: 2024-02-01

186  
papers

7,169  
citations

71102

41  
h-index

69250

77  
g-index

191  
all docs

191  
docs citations

191  
times ranked

12056  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories. <i>British Journal of Pain</i> , 2022, 16, 34-40.	1.5	22
2	Sustainable medicines development and use: Our collective responsibility for action to mitigate the natural world crisis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3013-3015.	2.4	2
3	Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coronersâ€™ case reports. <i>BJGP Open</i> , 2022, 6, BJGPO.2021.0150.	1.8	11
4	Ethics in clinical pharmacology: Facilitating public trust. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5-6.	2.4	1
5	Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity. <i>Drug Safety</i> , 2022, 45, 137-144.	3.2	15
6	When I use a word . . . . New medical words 1422â€“1972. <i>BMJ, The</i> , 2022, 376, o187.	6.0	2
7	When I use a word . . . . Lexicographical anniversaries. <i>BMJ, The</i> , 2022, 376, o105.	6.0	1
8	Sales of Over-the-Counter Products Containing Codeine in 31 Countries, 2013â€“2019: A Retrospective Observational Study. <i>Drug Safety</i> , 2022, 45, 237-247.	3.2	14
9	When I use a word . . . . Medical anniversaries in 2022. <i>BMJ, The</i> , 2022, 376, o39.	6.0	3
10	When I use a word . . . . Medical words newly logged in the OED in September 2021. <i>BMJ, The</i> , 2022, 376, o255.	6.0	2
11	Lessons from working across fields to develop a framework for informed choices. <i>Research for All</i> , 2022, 6, .	0.4	3
12	When I use a word . . . . Vaccinationâ€™rights and duties. <i>BMJ, The</i> , 2022, 376, o317.	6.0	0
13	When I use a word . . . . St Bartholomewâ€™onomastics and reputation. <i>BMJ, The</i> , 2022, 376, o370.	6.0	1
14	When I use a word . . . . Medical patronymics, metronymics, and papponymics. <i>BMJ, The</i> , 2022, 376, o437.	6.0	1
15	When I use a word . . . . Medical trigger warnings. <i>BMJ, The</i> , 2022, 376, o579.	6.0	0
16	When I use a word . . . . Diagnosis. <i>BMJ, The</i> , 2022, 376, o747.	6.0	2
17	When I use a word . . . . Memory, semantic and episodic. <i>BMJ, The</i> , 2022, 376, o804.	6.0	3
18	Placeboâ€™s invisible brother: a restricted scoping review of biomedical literature on the nocebo effect. <i>Pain</i> , 2022, Publish Ahead of Print, .	4.2	2

#	ARTICLE	IF	CITATIONS
19	When I use a word . . . . Listening to the patient. <i>BMJ, The</i> , 2022, 376, o646.	6.0	8
20	When I use a word . . . . Bioscience journalsâ€™an open and shut case?. <i>BMJ, The</i> , 2022, 376, o536.	6.0	0
21	When I use a word . . . . Medical aphorisms. <i>BMJ, The</i> , 2022, 377, o934.	6.0	0
22	Challenged comparison of tacrolimus assays. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 246-250.	1.2	3
23	When I use a word . . . . Remembrance of things past. <i>BMJ, The</i> , 2022, 377, o873.	6.0	1
24	Deaths attributed to the use of medications purchased online. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 60-64.	3.5	18
25	When I use a word . . . . Medical hyacinths. <i>BMJ, The</i> , 2022, 377, o1036.	6.0	0
26	When I use a word . . . . Medical magic. <i>BMJ, The</i> , 2022, 377, o1092.	6.0	1
27	When I use a word . . . . More medical magic. <i>BMJ, The</i> , 2022, 377, o1154.	6.0	0
28	Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations. <i>Drug Safety</i> , 2022, 45, 407-418.	3.2	17
29	When I use a word . . . . Some words about the climate. <i>BMJ, The</i> , 2022, 377, o1222.	6.0	0
30	A phase Ia/Ib study of intrathecal deferoxamine in patients with leptomeningeal metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2074-TPS2074.	1.6	1
31	On precision dosing of oral small molecule drugs in oncology. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 263-270.	2.4	3
32	The use of mechanistic reasoning in assessing coronavirus interventions. <i>Journal of Evaluation in Clinical Practice</i> , 2021, 27, 684-693.	1.8	8
33	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 225-245.	9.4	74
34	Coronersâ€™™ concerns to prevent harms: a series of coronersâ€™™ case reports to serve patient safety and educate the public, clinicians and policy-makers. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 37-38.	3.5	13
35	Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. <i>Pituitary</i> , 2021, 24, 170-183.	2.9	12
36	Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 112-113.	3.5	10

#	ARTICLE	IF	CITATIONS
37	Extracting data from diagnostic test accuracy studies for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 19-21.	3.5	2
38	Dealing with categorical risk data when extracting data for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 43-45.	3.5	3
39	Combining and converting groups when extracting data for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 85-87.	3.5	4
40	First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma. <i>Oncologist</i> , 2021, 26, 184-e366.	3.7	32
41	Summarising good practice guidelines for data extraction for systematic reviews and meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 88-90.	3.5	33
42	Nonmedical use of prescription drugs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1635-1636.	2.4	4
43	Was this Thomas Willis's greatest clinical success?. <i>Brain</i> , 2021, 144, e56-e56.	7.6	0
44	The Oxford Catalogue of Opioids: A systematic synthesis of opioid drug names and their pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3790-3812.	2.4	8
45	Introduction to clinical pharmacology at large. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3026-3027.	2.4	0
46	Was William Harvey's commitment to experimentation reflected in his clinical practice?. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 313-322.	2.0	1
47	Insulin Sensitivity After Living Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2021, 53, 1858-1864.	0.6	2
48	Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. <i>BMJ</i> , The, 2021, 374, n1537.	6.0	88
49	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-218.	1.0	1
50	Aspiration of conjugated bile acids predicts adverse lung transplant outcomes and correlates with airway lipid and cytokine dysregulation. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 998-1008.	0.6	18
51	Concise advice: Introducing a new clinically focused BJCP series on evidence-based (de)prescribing in challenging situations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4484-4487.	2.4	0
52	A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3K Inhibitor, in Patients with Metastatic Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5504.	3.7	18
53	When I use a word . . . The efficiency paradox. <i>BMJ</i> , The, 2021, 375, n2712.	6.0	1
54	When I use a word . . . Nasty medical eponyms. <i>BMJ</i> , The, 2021, 375, n2777.	6.0	0

#	ARTICLE	IF	CITATIONS
55	When I use a word . . . . No job, no job? A benefit:harm balance analysis. BMJ, The, 2021, 375, n2934.	6.0	3
56	When I use a word . . . . Examining the efficiency paradox. BMJ, The, 2021, 375, n2856.	6.0	0
57	When I use a word . . . . Taking therapeutic care. BMJ, The, 2021, 375, n3010.	6.0	2
58	When I use a word . . . . The Precautionary Principle: a definition. BMJ, The, 2021, 375, n3111.	6.0	3
59	When I use a word . . . . The Precautionary Principle: a brief history. BMJ, The, 2021, 375, n3059.	6.0	5
60	Why reports of clinical trials should include updated meta-analyses. BMJ Evidence-Based Medicine, 2020, 25, 1-2.	3.5	6
61	Clinical and translational pharmacology of bisphosphonates. , 2020, , 1671-1687.		1
62	Drug and therapeutics committees as guardians of safe and rational medicines use. British Journal of Clinical Pharmacology, 2020, 86, 10-12.	2.4	16
63	Naltrexone&bupropion (Mysimba) in management of obesity: A systematic review and meta&analysis of unpublished clinical study reports. British Journal of Clinical Pharmacology, 2020, 86, 646-667.	2.4	28
64	Medical Devices: Definition, Classification, and Regulatory Implications. Drug Safety, 2020, 43, 83-93.	3.2	47
65	COVID&19 vaccines: the importance of transparency and fact&based education. British Journal of Clinical Pharmacology, 2020, 86, 2107-2110.	2.4	13
66	Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature. Systematic Reviews, 2020, 9, 180.	5.3	3
67	Harms and the Xmas factor. BMJ, The, 2020, 371, m4067.	6.0	2
68	Me&too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. British Journal of Clinical Pharmacology, 2020, 86, 2114-2122.	2.4	37
69	Drugs and the renin-angiotensin system in covid-19. BMJ, The, 2020, 369, m1313.	6.0	89
70	Chloroquine and hydroxychloroquine in covid-19. BMJ, The, 2020, 369, m1432.	6.0	297
71	On the pharmacological evaluation of bisphosphonates in humans. Bone, 2020, 139, 115501.	2.9	15
72	Arsenic exposure associated T cell proliferation, smoking, and vitamin D in Bangladeshi men and women. PLoS ONE, 2020, 15, e0234965.	2.5	9

#	ARTICLE	IF	CITATIONS
73	NulelÃ-ntÃm Ã"li PaÃ"kw. British Journal of Clinical Pharmacology, 2020, 86, 8-9.	2.4	0
74	Remdesivir in covid-19. BMJ, The, 2020, 369, m1610.	6.0	91
75	Factors associated with the prescribing of high-dose opioids in primary care: a systematic review and meta-analysis. BMC Medicine, 2020, 18, 68.	5.5	25
76	Relation between opioid consumption and inclusion of opioids in 137 national essential medicines lists. BMJ Global Health, 2020, 5, e003563.	4.7	18
77	A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 2020, 133, 351-359.	1.6	1
78	Spotlight Commentary: ModelÃ- informed precision dosing must demonstrate improved patient outcomes. British Journal of Clinical Pharmacology, 2019, 85, 2238-2240.	2.4	17
79	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. BMJ Open, 2019, 9, e030596.	1.9	12
80	Pharmacometrics and systems pharmacology for metabolic bone diseases. British Journal of Clinical Pharmacology, 2019, 85, 1136-1146.	2.4	13
81	The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the British Medical Journal from 1955/6 to 1985/6. British Journal of Clinical Pharmacology, 2019, 85, 1901-1906.	2.4	3
82	A tetrahydrobiopterin deficit finding in schizophrenia: A confirmation study. Schizophrenia Research, 2019, 210, 316-318.	2.0	3
83	Bone turnover markers in women participating in a dose-finding trial of a contraceptive vaginal ring releasing Nestorone and estradiol. Contraception, 2019, 99, 329-334.	1.5	2
84	Drugs for the treatment of metabolic bone diseases. British Journal of Clinical Pharmacology, 2019, 85, 1049-1051.	2.4	7
85	Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. Clinical Cancer Research, 2019, 25, 5271-5283.	7.0	59
86	Lorcaserin in obesity: minimal benefits and ill-defined harms. BMJ Evidence-Based Medicine, 2019, 24, 145-146.	3.5	6
87	Withdrawn medicines included in the essential medicines lists of 136 countries. PLoS ONE, 2019, 14, e0225429.	2.5	7
88	Pharmacology of bisphosphonates. British Journal of Clinical Pharmacology, 2019, 85, 1052-1062.	2.4	132
89	Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights. BMJ Evidence-Based Medicine, 2019, 24, 127-129.	3.5	3
90	Comparison of essential medicines lists in 137 countries. Bulletin of the World Health Organization, 2019, 97, 394-404C.	3.3	67

#	ARTICLE	IF	CITATIONS
91	Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease. <i>Human Molecular Genetics</i> , 2018, 27, 1545-1555.	2.9	38
92	Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980). <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1668-1685.	2.4	7
93	Variation in diagnostic test requests and outcomes: a preliminary metric for OpenPathology.net. <i>Scientific Reports</i> , 2018, 8, 4752.	3.3	12
94	Overtesting and undertesting in primary care: a systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e018557.	1.9	80
95	Overdiagnosis: what it is and what it isn't. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 1-3.	3.5	191
96	Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis. <i>Obesity</i> , 2018, 26, 513-521.	3.0	4
97	Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	43
98	Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin. <i>Statistical Methods in Medical Research</i> , 2018, 27, 564-578.	1.5	6
99	The toxicological significance of post-mortem drug concentrations in bile. <i>Clinical Toxicology</i> , 2018, 56, 7-14.	1.9	17
100	Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 252-267.	2.4	35
101	Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 63-72.	2.4	18
102	A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. <i>Blood</i> , 2018, 131, 397-407.	1.4	109
103	Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015/16. <i>BMC Medicine</i> , 2018, 16, 229.	5.5	21
104	Oral hormone pregnancy tests and the risks of congenital malformations: a systematic review and meta-analysis. <i>F1000Research</i> , 2018, 7, 1725.	1.6	8
105	Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. <i>Aids</i> , 2018, 32, 2517-2524.	2.2	5
106	Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. <i>BMJ: British Medical Journal</i> , 2018, 363, k4666.	2.3	91
107	Examining the "psychopharmacology revolution" (1950-1980) through the advertising of psychoactive drugs in the <i>British Medical Journal</i> . <i>Journal of Psychopharmacology</i> , 2018, 32, 1056-1066.	4.0	5
108	The use of mechanistic evidence in drug approval. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 1166-1176.	1.8	23

#	ARTICLE	IF	CITATIONS
109	Reduced Salt Intake for Heart Failure. JAMA Internal Medicine, 2018, 178, 1693.	5.1	65
110	Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. Blood Advances, 2018, 2, 969-978.	5.2	24
111	Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. Pharmacotherapy, 2018, 38, 730-738.	2.6	36
112	What is a "complex systematic review"? Criteria, definition, and examples. BMJ Evidence-Based Medicine, 2018, 23, 127-130.	3.5	10
113	Redefining rapid reviews: a flexible framework for restricted systematic reviews. BMJ Evidence-Based Medicine, 2018, 23, 201-203.	3.5	90
114	Serum glutamine and hospital-acquired infections after aneurysmal subarachnoid hemorrhage. Neurology, 2018, 91, e421-e426.	1.1	9
115	A word about evidence: "rapid reviews" or "restricted reviews"? BMJ Evidence-Based Medicine, 2018, 23, 204-205.	3.5	15
116	Prescribing biosimilars. BMJ: British Medical Journal, 2018, 362, k3141.	2.3	10
117	A basal gene expression signature to predict for synergy of combined EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.. Journal of Clinical Oncology, 2018, 36, 7546-7546.	1.6	0
118	Defining "nutraceuticals": neither nutritious nor pharmaceutical. British Journal of Clinical Pharmacology, 2017, 83, 8-19.	2.4	158
119	Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception, 2017, 95, 398-404.	1.5	14
120	Poor medication adherence in clinical trials: consequences and solutions. Nature Reviews Drug Discovery, 2017, 16, 149-150.	46.4	58
121	Endogenous thrombin potential changes during the first cycle of oral contraceptive use. Contraception, 2017, 95, 456-463.	1.5	16
122	Multivalent Small-Molecule Pan-RAS Inhibitors. Cell, 2017, 168, 878-889.e29.	28.9	213
123	Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception, 2017, 95, 464-469.	1.5	45
124	Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5 $\alpha$ -reductase Inhibition. European Urology, 2017, 72, 499-506.	1.9	16
125	Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD. Journal of Molecular and Cellular Cardiology, 2017, 112, 114-122.	1.9	31
126	CARE guidelines for case reports: explanation and elaboration document. Journal of Clinical Epidemiology, 2017, 89, 218-235.	5.0	993



#	ARTICLE	IF	CITATIONS
127	A UPLC-MS/MS method for the quantitation of Ulipristal acetate in human serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1059, 43-48.	2.3	4
128	Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification. <i>Drug Safety</i> , 2017, 40, 431-441.	3.2	7
129	Biomarkers—A General Review. <i>Current Protocols in Pharmacology</i> , 2017, 76, 9.23.1-9.23.17.	4.0	196
130	Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib. <i>Clinical Cancer Research</i> , 2017, 23, 3084-3096.	7.0	23
131	Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950—Metabolites in Frozen Human Plasma. <i>Journal of Lipid Research</i> , 2017, 58, 2275-2288.	4.2	312
132	Drugs for rare disorders. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1607-1613.	2.4	21
133	Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems. <i>Therapie</i> , 2017, 72, 555-561.	1.0	20
134	Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1328-1337.	1.9	2
135	Unlicensed and off-label uses of medicines: definitions and clarification of terminology. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2615-2625.	2.4	55
136	Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process. <i>BMJ Open</i> , 2017, 7, e017125.	1.9	64
137	Journal Clubs: 1. Origins. <i>Evidence-Based Medicine</i> , 2017, 22, 231-231.	0.6	6
138	Journal Clubs: 2. Why and how to run them and how to publish them. <i>Evidence-Based Medicine</i> , 2017, 22, 232-234.	0.6	18
139	Vitamin D Storage in Adipose Tissue of Obese and Normal Weight Women. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 237-242.	2.8	138
140	Sclerostin measurement in human disease: Validity and current limitations. <i>Bone</i> , 2017, 96, 24-28.	2.9	18
141	Maternal serum cytokine levels and risk of bipolar disorder. <i>Brain, Behavior, and Immunity</i> , 2017, 63, 108-114.	4.1	16
142	Transvaginal mesh failure: lessons for regulation of implantable devices. <i>BMJ: British Medical Journal</i> , 2017, 359, j5515.	2.3	45
143	Non-existent authors. <i>BMJ: British Medical Journal</i> , 2017, 359, j5706.	2.3	2
144	Targeted inhibition of glutaminase as a potential new approach for the treatment of NF1-associated soft tissue malignancies. <i>Oncotarget</i> , 2017, 8, 94054-94068.	1.8	26

#	ARTICLE	IF	CITATIONS
145	Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. <i>BMC Medicine</i> , 2016, 14, 191.	5.5	113
146	How similar are biosimilars?. <i>BMJ, The</i> , 2016, 353, i2721.	6.0	11
147	Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. <i>BMC Medicine</i> , 2016, 14, 10.	5.5	384
148	Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard -Negative Controls™ by the Observational Medical Outcomes Partnership (OMOP). <i>Drug Safety</i> , 2016, 39, 421-432.	3.2	25
149	Impaired postprandial lipemic response in chronic kidney disease. <i>Kidney International</i> , 2016, 90, 172-180.	5.2	14
150	Therapeutic drug monitoring in the era of precision medicine: opportunities!. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 900-902.	2.4	29
151	The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 56-61.	2.4	19
152	Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 52-55.	2.4	21
153	Inhibiting the proton pump: mechanisms, benefits, harms, and questions. <i>BMC Medicine</i> , 2016, 14, 172.	5.5	14
154	Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)-variants in the spellings of drug names in PubMed: a database review. <i>BMJ, The</i> , 2016, 355, i4854.	6.0	6
155	Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2742-2750.	3.6	101
156	Palmitic Acid Reduces Circulating Bone Formation Markers in Obese Animals and Impairs Osteoblast Activity via C16-Ceramide Accumulation. <i>Calcified Tissue International</i> , 2016, 98, 511-519.	3.1	37
157	Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year. <i>Contraception</i> , 2016, 93, 263-265.	1.5	26
158	Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. <i>Critical Reviews in Toxicology</i> , 2016, 46, 477-489.	3.9	86
159	Clotting factor changes during the first cycle of oral contraceptive use. <i>Contraception</i> , 2016, 93, 70-76.	1.5	15
160	How a VOICE for clinical pharmacology turns into a RECIPE for its development. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 1.	0.9	1
161	Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 399-409.	3.1	3
162	A systematic evaluation of collagen cross-links in the human cervix. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 321.e1-321.e8.	1.3	47

#	ARTICLE	IF	CITATIONS
163	Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. <i>Endocrine</i> , 2015, 50, 504-507.	2.3	5
164	Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 4663-4675.	7.0	80
165	Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity. <i>Diabetes</i> , 2015, 64, 3396-3405.	0.6	31
166	Estimating systemic exposure to ethinyl estradiol from an oral contraceptive. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 614.e1-614.e7.	1.3	8
167	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 2096-2106.	7.0	48
168	Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 4097-4109.	7.0	41
169	Medication errors detected in non-traditional databases: types of errors in methotrexate dosing as listed in four different Danish registers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1375-1379.	1.9	14
170	Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4208-4214.	3.6	33
171	Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. <i>Cancer Causes and Control</i> , 2015, 26, 187-203.	1.8	60
172	Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names. <i>PLoS ONE</i> , 2015, 10, e0145431.	2.5	15
173	The Need for Randomization in Animal Trials: An Overview of Systematic Reviews. <i>PLoS ONE</i> , 2014, 9, e98856.	2.5	199
174	Medical eponyms: taxonomies, natural history, and the evidence. <i>BMJ</i> , The, 2014, 349, g7586-g7586.	6.0	14
175	Quantitative Evaluation of Collagen Crosslinks and Corresponding Tensile Mechanical Properties in Mouse Cervical Tissue during Normal Pregnancy. <i>PLoS ONE</i> , 2014, 9, e112391.	2.5	102
176	Balanced prescribing "principles and challenges. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 566-572.	2.4	29
177	Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate.. <i>Blood</i> , 2012, 120, 2758-2758.	1.4	1
178	Pharmacology of bisphosphonates. <i>Bone</i> , 2011, 49, 42-49.	2.9	176
179	Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. <i>Annals of the New York Academy of Sciences</i> , 2011, 1218, 80-87.	3.8	23
180	A manifesto for clinical pharmacology from principles to practice. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 3-13.	2.4	41

#	ARTICLE	IF	CITATIONS
181	Bone markers–new aspects. <i>Clinical Laboratory</i> , 2008, 54, 461-71.	0.5	6
182	Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease. <i>Drugs</i> , 2006, 66, 2031-2058.	10.9	76
183	Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 249-256.	2.4	82
184	A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. <i>European Journal of Clinical Pharmacology</i> , 2002, 57, 883-890.	1.9	66
185	Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 386-389.	2.4	49
186	Adverse events in patients taking cephalosporins versus placebo for any indication. <i>The Cochrane Library</i> , 0, , .	2.8	0